Agents which regulate, inhibit, or modulate the activity and/or expression of formyl peptide receptors as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

A method for lowering intraocular pressure in a patient in need thereof, said method comprising administering a therapeutically effective amount of a composition comprising at least one non-nucleotide or non-protein agent that inhibits expression, signaling, or biological functions of connective tissue growth factor (FPR), and a pharmaceutically acceptable carrier.

A method for preventing the visual field loss associated with Primary Open Angle Glaucoma (POAG), said method comprising administering to a patient in need thereof a composition comprising a non-nucleotide or non-protein agent that modulates the expression of FPR such that intraocular pressure is controlled and protection is provided to retinal ganglion cells or to the optic nerve head.

A composition for lowering intraocular pressure and providing neuroprotection in a patient in need thereof, said composition comprising at least one agent that inhibits the expression, signaling, or biological functions of FPR and a pharmaceutically acceptable carrier.